NCT06385483 2026-03-19Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)National Cancer Institute (NCI)Phase 2 Active not recruiting19 enrolled 10 charts
NCT02979977 2026-02-04Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and NeckYale UniversityPhase 2 Completed50 enrolled 14 charts